Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States

Jason Shafrin; Kejal Jadhav; Cheryl Warren; Sabiha Quddus; Nadine K Zawadzki; Daisy Yang; Andrea Damon; Kathryn Spurrier; Katharine Batt; David Wei; Jason Shafrin; Kejal Jadhav; Cheryl Warren; Sabiha Quddus; Nadine K Zawadzki; Daisy Yang; Andrea Damon; Kathryn Spurrier; Katharine Batt; David Wei

doi:10.1080/13696998.2025.2593796

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

These findings highlight the significant uncompensated burden placed on oncology practices, raising concerns about how non-reimbursed tasks may affect patient care, staff retention, and the financial sustainability of these practices.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shafrin et al. (2025) studied this question.

synapsesocial.com/papers/694035f32d562116f29091e3 https://doi.org/10.1080/13696998.2025.2593796

View Full Paper

Ask AI

Bookmark

Share

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States

Ask about this paper

Abstract

Discussion

Cite This Study

Chronic myeloid leukemia treatment intolerance imposes additional resource and economic burden on oncology practices in the United States

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading